Pain Therapeutics (PTIE) 2.24 $PTIE
Global Pain Therapeutics Market Report: Market Trends & R&D Insights 2015-2020 - By 2020, the Leading Branded Opioids Will Generate Over $6.6 Billion in Worldwide Revenues - Research and Markets
PR Newswire Europe - Mon Jul 04, 2:11PM CDT
DUBLIN, July 04, 2016 /PRNewswire/ --
PTIE: 2.24 (+0.03)
DURECT Provides REMOXY® Update
PR Newswire - Fri Jul 01, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that the U.S. Food and Drug Administration (FDA) has determined that an Advisory Committee meeting for REMOXY®, which had been tentatively scheduled for August 5, 2016, is unnecessary and will not be held. REMOXY was previously the subject of an Advisory Committee meeting in 2008. Pain Therapeutics also stated that the FDA advised them that the regulatory review of the REMOXY New Drug Application (NDA) remains active and on-going. The Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA of September 25, 2016 is unchanged.
DRRX: 1.27 (+0.07), PTIE: 2.24 (+0.03)
Pain Therapeutics Announces Advisory Committee Meeting for REMOXY(R) Is Not Needed
GlobeNewswire - Fri Jul 01, 8:00AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) announced today that the U.S. Food and Drug Administration (FDA) has determined that an Advisory Committee meeting for REMOXY, which had been tentatively scheduled for August 5th, is unnecessary and will not be held. FDA also advised that the regulatory review of the REMOXY NDA remains active and on-going. The Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA is unchanged.
PTIE: 2.24 (+0.03)
Global Pain Therapeutics Market Trends & R&D Insights, 2020
GlobeNewswire - Thu Jun 30, 4:02AM CDT
Research and Markets has announced the addition of the "The Global Pain Therapeutics Market, 5th Edition: Market Trends & R&D Insights" report to their offering.
PTIE: 2.24 (+0.03)
Global Pain Therapeutics Market Report: Market Trends & R&D Insights 2015-2020 - Research and Markets
BusinessWire - Wed Jun 29, 3:51AM CDT
Research and Markets has announced the addition of the "The Global Pain Therapeutics Market, 5th Edition: Market Trends & R&D Insights" report to their offering.
PTIE: 2.24 (+0.03)
Global Pain Therapeutics Report 2016 - Focus on Latest Drugs, Markets and Companies - Research and Markets
PR Newswire Europe - Fri May 27, 7:10AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/thf6d3/pain_therapeutics] to their offering.
PTIE: 2.24 (+0.03)
Global Pain Therapeutics Report 2016-2025 - Drugs, Markets and Companies Forecasts
GlobeNewswire - Fri May 27, 3:17AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.24 (+0.03)
Global Peripheral Neuropathic Pain Therapeutics Pipeline Report 2016 - 10 Companies & Drug Profiles - Research and Markets
BusinessWire - Thu May 26, 8:36AM CDT
Research and Markets has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.24 (+0.03)
DURECT Announces FDA Advisory Committee Meeting for REMOXY®
PR Newswire - Thu May 19, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), in a joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee tentatively scheduled for August 5, 2016. Pain Therapeutics also stated that the FDA advised them that the Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA of September 25, 2016 is unchanged.
DRRX: 1.27 (+0.07), PTIE: 2.24 (+0.03)
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY(R)
GlobeNewswire - Thu May 19, 8:00AM CDT
- August 5 is FDA's Tentative Date for Advisory Committee Meeting -
PTIE: 2.24 (+0.03)
Pain Therapeutics to Present New REMOXY Data At American Pain Society Meeting
GlobeNewswire - Wed May 11, 8:05AM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) today announced that researchers will present new data around REMOXY's abuse-deterrent properties at the 35 Annual Scientific Meeting of the American Pain Society (APS), held this year in Austin, TX.
PTIE: 2.24 (+0.03)
DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting
PR Newswire - Wed May 11, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting. The scientific poster is titled "REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation." Co-authors Lynn Webster and Nadav Friedmann are scheduled to present the data at APS on Thursday, May 12, 2016, from 3:45 to 5:15 pm Central Time. This scientific poster will be available for review by the general public on DURECT's website at www.durect.com.
DRRX: 1.27 (+0.07), PTIE: 2.24 (+0.03)
Pain Therapeutics Reports Q1 2016 Financial Results
GlobeNewswire - Thu May 05, 3:05PM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) today reported financial results for the first quarter of 2016. Net loss in Q1 2016 was $5.8 million, or $0.13 per share, compared to a net loss in Q1 2015 of $2.6 million, or $0.06 per share.
PTIE: 2.24 (+0.03)
Global Visceral Pain Therapeutics Pipeline Report 2016 - Research and Markets
BusinessWire - Thu Apr 28, 1:06PM CDT
Research and Markets has announced the addition of the "Visceral Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.24 (+0.03)
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016
GlobeNewswire - Tue Apr 12, 3:05PM CDT
- Company Will Host Conference Call on Wednesday, April 13, 8:30am EDT -
PTIE: 2.24 (+0.03)
Diabetic Neuropathic Pain Therapeutics Pipeline Review H1 2016 - Research and Markets
BusinessWire - Wed Mar 30, 1:54PM CDT
Research and Markets has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.24 (+0.03)
Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim
BusinessWire - Wed Mar 30, 6:00AM CDT
--Acquisition Creates One of the Largest Exclusively Pain-Focused, Non-Opioid Pipelines in Active Development
PTIE: 2.24 (+0.03)
DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug Administration
PR Newswire - Tue Mar 29, 10:15AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA). Pain Therapeutics has stated that they expect to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review Designation.
DRRX: 1.27 (+0.07), PTIE: 2.24 (+0.03)
Global Pain Therapeutics Market Report: Market Trends & R&D Insights 2015-2020 - By 2020, the Leading Branded Opioids Will Generate Over $6.6 Billion in Worldwide Revenues - Research and Markets
PR Newswire Europe - Mon Jul 04, 2:11PM CDT
DUBLIN, July 04, 2016 /PRNewswire/ --
PTIE: 2.24 (+0.03)
DURECT Provides REMOXY® Update
PR Newswire - Fri Jul 01, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that the U.S. Food and Drug Administration (FDA) has determined that an Advisory Committee meeting for REMOXY®, which had been tentatively scheduled for August 5, 2016, is unnecessary and will not be held. REMOXY was previously the subject of an Advisory Committee meeting in 2008. Pain Therapeutics also stated that the FDA advised them that the regulatory review of the REMOXY New Drug Application (NDA) remains active and on-going. The Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA of September 25, 2016 is unchanged.
DRRX: 1.27 (+0.07), PTIE: 2.24 (+0.03)
Pain Therapeutics Announces Advisory Committee Meeting for REMOXY(R) Is Not Needed
GlobeNewswire - Fri Jul 01, 8:00AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) announced today that the U.S. Food and Drug Administration (FDA) has determined that an Advisory Committee meeting for REMOXY, which had been tentatively scheduled for August 5th, is unnecessary and will not be held. FDA also advised that the regulatory review of the REMOXY NDA remains active and on-going. The Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA is unchanged. PTIE: 2.24 (+0.03)
Global Pain Therapeutics Market Trends & R&D Insights, 2020
GlobeNewswire - Thu Jun 30, 4:02AM CDT
Research and Markets has announced the addition of the "The Global Pain Therapeutics Market, 5th Edition: Market Trends & R&D Insights" report to their offering.
PTIE: 2.24 (+0.03)
Global Pain Therapeutics Market Report: Market Trends & R&D Insights 2015-2020 - Research and Markets
BusinessWire - Wed Jun 29, 3:51AM CDT
Research and Markets has announced the addition of the "The Global Pain Therapeutics Market, 5th Edition: Market Trends & R&D Insights" report to their offering.
PTIE: 2.24 (+0.03)
Global Pain Therapeutics Report 2016 - Focus on Latest Drugs, Markets and Companies - Research and Markets
PR Newswire Europe - Fri May 27, 7:10AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/thf6d3/pain_therapeutics] to their offering.
PTIE: 2.24 (+0.03)
Global Pain Therapeutics Report 2016-2025 - Drugs, Markets and Companies Forecasts
GlobeNewswire - Fri May 27, 3:17AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.24 (+0.03)
Global Peripheral Neuropathic Pain Therapeutics Pipeline Report 2016 - 10 Companies & Drug Profiles - Research and Markets
BusinessWire - Thu May 26, 8:36AM CDT
Research and Markets has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.24 (+0.03)
DURECT Announces FDA Advisory Committee Meeting for REMOXY®
PR Newswire - Thu May 19, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), in a joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee tentatively scheduled for August 5, 2016. Pain Therapeutics also stated that the FDA advised them that the Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA of September 25, 2016 is unchanged.
DRRX: 1.27 (+0.07), PTIE: 2.24 (+0.03)
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY(R)
GlobeNewswire - Thu May 19, 8:00AM CDT
- August 5 is FDA's Tentative Date for Advisory Committee Meeting -
PTIE: 2.24 (+0.03)
Pain Therapeutics to Present New REMOXY Data At American Pain Society Meeting
GlobeNewswire - Wed May 11, 8:05AM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that researchers will present new data around REMOXY's abuse-deterrent properties at the 35 Annual Scientific Meeting of the American Pain Society (APS), held this year in Austin, TX. PTIE: 2.24 (+0.03)
DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting
PR Newswire - Wed May 11, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting. The scientific poster is titled "REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation." Co-authors Lynn Webster and Nadav Friedmann are scheduled to present the data at APS on Thursday, May 12, 2016, from 3:45 to 5:15 pm Central Time. This scientific poster will be available for review by the general public on DURECT's website at www.durect.com.
DRRX: 1.27 (+0.07), PTIE: 2.24 (+0.03)
Pain Therapeutics Reports Q1 2016 Financial Results
GlobeNewswire - Thu May 05, 3:05PM CDT
Pain Therapeutics, Inc. (Nasdaq
TIE) today reported financial results for the first quarter of 2016. Net loss in Q1 2016 was $5.8 million, or $0.13 per share, compared to a net loss in Q1 2015 of $2.6 million, or $0.06 per share. PTIE: 2.24 (+0.03)
Global Visceral Pain Therapeutics Pipeline Report 2016 - Research and Markets
BusinessWire - Thu Apr 28, 1:06PM CDT
Research and Markets has announced the addition of the "Visceral Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.24 (+0.03)
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016
GlobeNewswire - Tue Apr 12, 3:05PM CDT
- Company Will Host Conference Call on Wednesday, April 13, 8:30am EDT -
PTIE: 2.24 (+0.03)
Diabetic Neuropathic Pain Therapeutics Pipeline Review H1 2016 - Research and Markets
BusinessWire - Wed Mar 30, 1:54PM CDT
Research and Markets has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.24 (+0.03)
Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim
BusinessWire - Wed Mar 30, 6:00AM CDT
--Acquisition Creates One of the Largest Exclusively Pain-Focused, Non-Opioid Pipelines in Active Development
PTIE: 2.24 (+0.03)
DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug Administration
PR Newswire - Tue Mar 29, 10:15AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA). Pain Therapeutics has stated that they expect to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review Designation.
DRRX: 1.27 (+0.07), PTIE: 2.24 (+0.03)
